Phase 3 N=29 Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
Fuchs Endothelial Dystrophy
Primary: Change in Central Corneal Thickness — -23; -2 microns
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=25 Safety Study of Hepatitis E Vaccine (HEV239)
Hepatitis E · Immunisation
Primary: Number of Participants With Solicited Local Reactogenicity Events — 11; 3; 17; 1 Participants
Phase 2 N=97 Assessing Symptomatic Clinical Episodes in Depression
Major Depressive Disorder
Primary: MADRS Score - Overall Change From Baseline — 13.7; 8.8 score on a scale — p=<.001
N/A N=60 Onduo Virtual Diabetes Clinic Study
Diabetes Mellitus, Type 2
Primary: Mean Change in Hemoglobin A1c — -1.6 Percent (%)
Phase 2 N=34 A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Glioblastoma
Primary: Dose-limiting Toxicities (DLTs) — 0; 0 Participants
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
Phase 1 N=45 Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
COVID-19
Primary: Frequency of Occurrence of Neutropenia ≥ Grade 3 — 0; 0; 0; 0 Participants
Phase 3 N=999 Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma
Asthma
Primary: Baseline-adjusted Area Under the Serial FEV1-time Curve Calculated From Time Zero to 12 Hours (AUC0-12h) on Day 1 of Treatment — 4.03; 3.96 liters x hours
Phase 2 N=64 Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia · Advanced Myelodysplastic Syndromes
Primary: To Reduce the Early Transplant-related Mortality.
N/A N=51 Cardiovascular Complications of Sickle Cell Disease
Sickle Cell Disease
Primary: MRI Parameter - LVEDVi, mL/cm2 (Measured Using Method of Disks, Controls Serve as Normal Ranges) — 124.0; 78.7 mL/cm2 — p=0.0039
Phase 2 N=21 Apremilast in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP) (APLANTUS)
Palmoplantar Pustulosis
Primary: Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI) at Week 20 Compared With Baseline — 16.50; 15.85; 16.50; 7.65 PPPASI Score — p=< 0.0001
Phase 3 N=602 A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection
Colorectal Surgery · Surgical Wound Infection
Primary: Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 60 — 90; 63 Participants
Phase 4 N=246 DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
Ventricular Tachycardia · Premature Ventricular Contraction · Stroke
Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001
Phase 2 N=20 Combination Facial Aesthetic Treatment in Millennials
Dermatological Non-Disease
Primary: FACE-Q Satisfaction With Facial Appearance Overall Scale — 42.35; 59.42 score on a scale
Phase 2 N=65 Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Neutropenia
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs) — 4 Participants